New hope for tough leukemia: Triple-Drug attack under study

NCT ID NCT03041688

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safest dose and understand side effects. About 58 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA SECONDARY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Keck Medical Center of USC Pasadena

Pasadena, California, 91105, United States
Los Angeles General Medical Center

Los Angeles, California, 90033, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.